Valuation: Ind-Swift Laboratories Limited

Market Cap 11.4B 118M 103M 95.43M 87.96M 166M 169M 1.14B 449M 5.58B 444M 435M 19.21B P/E 2024
1.41x
P/E 2025 2.38x
Enterprise Value 7.13B 74.05M 64.71M 59.71M 55.04M 104M 106M 714M 281M 3.49B 278M 272M 12.02B EV / Sales 2024
0.14x
EV / Sales 2025 0.12x
Free-Float
40.72%
Yield 2024 *
-
Yield 2025 -
1 day+1.09%
1 week-1.56%
Current month+14.97%
1 month+23.88%
3 months+68.46%
6 months+117.83%
Current year+165.45%
1 week 220.02
Extreme 220.02
238.3
1 month 187.87
Extreme 187.87
248.45
Current year 87.25
Extreme 87.25
248.45
1 year 87.15
Extreme 87.15
248.45
3 years 68.72
Extreme 68.72
248.45
5 years 52.65
Extreme 52.65
248.45
10 years 15
Extreme 15
248.45
Manager TitleAgeSince
Chief Executive Officer 74 1995-01-03
Chief Executive Officer 43 2011-06-14
Director of Finance/CFO - 2018-09-28
Director TitleAgeSince
Director/Board Member 43 -
Chairman 74 -
Director/Board Member 35 2010-03-22
Date Insider Type Main position Quantity % Market Cap.
9/12/24 Sell

Chief Financial Officer

30,000 0.0508%
Change 5-day change 1-year change 3-year change Capi.($)
+1.09%-1.56%+120.72%+156.43% 208M
+1.23%+1.82%+15.61%+78.24% 48.15B
-0.23%-1.65%+67.15%+109.36% 35.59B
+1.61%+1.04%-2.19%+36.44% 11.9B
+0.46%+1.56%+18.45%+86.06% 11.85B
+0.93%+2.87%+34.92%+137.61% 9.31B
+3.37%-0.10%+51.64%-4.77% 7.02B
+0.17%+0.76%+16.63%+35.40% 6.91B
-.--%+0.14% - - 6.79B
+0.18%-2.69%+2.50%+202.37% 6.55B
Average +0.87%-1.16%+36.16%+93.02% 14.43B
Weighted average by Cap. +0.76%-0.69%+30.39%+87.01%

Financials

2024 2025
Net sales 12.97B 135M 118M 109M 100M 189M 193M 1.3B 511M 6.35B 506M 495M 21.87B 5.62B 58.33M 50.97M 47.04M 43.36M 81.72M 83.53M 562M 221M 2.75B 219M 214M 9.47B
Net income 4.21B 43.71M 38.2M 35.25M 32.49M 61.24M 62.6M 421M 166M 2.06B 164M 161M 7.1B 2.5B 26.01M 22.73M 20.97M 19.33M 36.44M 37.25M 251M 98.61M 1.23B 97.68M 95.54M 4.22B
Net Debt -4.15B -43.13M -37.69M -34.78M -32.06M -60.42M -61.76M -416M -163M -2.03B -162M -158M -7B -4.27B -44.29M -38.71M -35.72M -32.92M -62.05M -63.43M -427M -168M -2.09B -166M -163M -7.19B
Logo Ind-Swift Laboratories Limited
Ind-Swift Laboratories Limited is an India-based company, which is engaged in the business of manufacturing active pharmaceutical ingredients (APIs), intermediates and formulations. The Company operates in the Pharmaceutical Business segment. It also focuses on manufacturing formulations. The Company’s products include APIs and Impurities. Its APIs therapeutic category includes Macrolide Antibiotic, Cardiovascular, Antihistaminic, Antidiabetic, Antipsyhotic, Bone Resorption Inhibitor, and Aromatase Inhibitor. Its products include Clarithromycin, Clarithromycin Coated Granules, Clarithromycin Citrate, Atorvastatin Calcium Crystalline, Atorvastatin Calcium Amorphous, Clopidogrel HCl, Ezetimibe, Ivabradine Oxalate, Ranolazine, Aripiprazole, Risedronate Sodium, Ropinirole HCl, Cinacalcet HCl, Letrozole, and Anastrozole. Its products under development include Sitagliptin Phosphate, Mirabegron, Bempedoic Acid, Lasmiditan, and Eltrombopag Olamine.
Employees
1,246
Date Price Change Volume
26-07-20 233.99 +1.09% 438,766
26-07-17 ₹231.47 -1.03% 288,534
26-07-16 ₹233.89 +3.12% 562,319
26-07-15 ₹226.82 -1.32% 619,285
26-07-14 ₹229.86 -3.30% 780,003
  1. Stock Market
  2. Stocks
  3. INDSWFTLAB Stock